FDA likely to approve Biogen’s aducanumab for Alzheimer’s disease after its review

alzheimers
There is a high unmet need for DMTs in AD as the current competitive landscape offers six medications that are aimed at treating the symptoms of the disease. Credit: pathdoc/Shutterstock.